Esteban Ribera

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4192728/publications.pdf

Version: 2024-02-01

30	940	566801 15	454577 30
papers	citations	h-index	g-index

31	31	31	1521
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations. PLoS Pathogens, 2019, 15, e1007991.	2.1	119
2	A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4 ⁺ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients. MBio, 2017, 8, .	1.8	105
3	The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases, 2015, 61, 403-408.	2.9	100
4	Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. Clinical Infectious Diseases, 2017, 65, 2112-2118.	2.9	88
5	Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. Journal of Antimicrobial Chemotherapy, 2007, 59, 690-697.	1.3	71
6	Steady-State Pharmacokinetics of a Double-Boosting Regimen of Saquinavir Soft Gel plus Lopinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Infected Adults. Antimicrobial Agents and Chemotherapy, 2004, 48, 4256-4262.	1.4	56
7	Improvements in Subcutaneous Fat, Lipid Profile, and Parameters of Mitochondrial Toxicity in Patients with Peripheral Lipoatrophy When Stavudine is Switched to Tenofovir (LIPOTEST Study). HIV Clinical Trials, 2008, 9, 407-417.	2.0	56
8	Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. Aids, 2006, 20, 1131-1139.	1.0	45
9	Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab. Nature Communications, 2019, 10, 3705.	5.8	38
10	Epidemiology of infections by HIV, Syphilis, Gonorrhea and Lymphogranuloma Venereum in Barcelona City: a population-based incidence study. BMC Public Health, 2015, 15, 1015.	1.2	37
11	Once-Daily Regimen of Saquinavir, Ritonavir, Didanosine, and Lamivudine in HIV-Infected Patients With Standard Tuberculosis Therapy (TBQD Study). Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 317-323.	0.9	26
12	Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial. Clinical Infectious Diseases, 2015, 60, 811-820.	2.9	26
13	Early Antiviral Treatment of Hepatitis C Virus Recurrence after Liver Transplantation in HIV-Infected Patients. Antiviral Therapy, 2006, 11, 1061-1070.	0.6	23
14	Early Monitoring of Ribavirin Serum Concentration is not Useful to Optimize Hepatitis C Virus treatment in HIV-Coinfected Patients. Antiviral Therapy, 2007, 12, 1217-1224.	0.6	20
15	Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study. Journal of Antimicrobial Chemotherapy, 2014, 70, 1130-8.	1.3	18
16	Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus. Pharmacotherapy, 2019, 39, 501-507.	1.2	15
17	Efficacy and Safety of Once-Daily Combination Therapy with Didanosine, Lamivudine and Nevirapine in Antiretroviral-Naive HIV-Infected Patients. Antiviral Therapy, 2005, 10, 605-614.	0.6	14
18	Double-Boosted Protease Inhibitor Antiretroviral Regimens. Drugs, 2008, 68, 2257-2267.	4.9	11

#	Article	IF	Citations
19	Acute Leg Ischaemia in an HIV-Infected Patient Receiving Antiretroviral Treatment. Antiviral Therapy, 2017, 22, 89-90.	0.6	10
20	Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial. Journal of Clinical Medicine, 2020, 9, 1246.	1.0	9
21	Effectiveness and safety of an abacavir/lamivudineâ€Š+â€Šrilpivirine regimen for the treatment of HIV-1 infection in naive patients. Journal of Antimicrobial Chemotherapy, 2016, 71, 3510-3514.	1.3	7
22	Antiretroviral Therapy in Advanced HIV Disease: Which is the Best Regimen?. AIDS Reviews, 2018, 20, 3-13.	0.5	7
23	Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC. Journal of the International AIDS Society, 2014, 17, 19550.	1.2	6
24	New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy. AIDS Reviews, 2019, 20, 179-186.	0.5	5
25	Darunavir and Ritonavir Total and Unbound Plasmatic Concentrations in HIV-HCV-Coinfected Patients with Hepatic Cirrhosis Compared to Those in HIV-Monoinfected Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 6782-6790.	1.4	4
26	Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. Journal of Antimicrobial Chemotherapy, 2020, 75, 1955-1960.	1.3	4
27	Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, , .	0.3	4
28	Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Antiviral Therapy, 2005, 10, 605-14.	0.6	3
29	Impacto econÃ³mico asociado a la implementaciÃ³n de las recomendaciones con grado de evidencia A- I del documento de consenso de GeSIDA/PNS (2015) relativas a la optimizaciÃ³n del tratamiento antirretroviral en adultos infectados por virus de la inmunodeficiencia humana con carga viral suprimida en EspaÃ±a. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 157-164.	0.3	1
30	Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy. HIV Clinical Trials, 2017, 18, 49-53.	2.0	0